Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

被引：0
|
作者：
Alsina, Maria [1 ]
Fleitas-Kanonnikoff, Tania [2 ]
机构：
[1] Hosp Univ Navarra, Med Oncol Dept, Translat Med Oncol Invest Grp, Navarrabiomed IdiSNA, C-Irunlarrea 3, Pamplona 35008, Spain
[2] Hosp Clin Univ Valencia, Med Oncol Dept, INCLIVA, Valencia, Spain
来源：
MED | 2024年 / 5卷 / 09期
关键词：
CHEMOTHERAPY; PLACEBO;
D O I：
10.1016/j.medj.2024.05.016
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.(1)
引用
收藏
页码：1038 / 1040
页数：3
相关论文
共 50 条
  • [41] Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma
    Rogers, Jane E.
    Yamashita, Kohei
    Sewastjanow-Silva, Matheus
    Rosa Vicentini, Ernesto
    Waters, Rebecca
    Ajani, Jaffer A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 565 - 571
  • [42] The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma
    Chen, Ming-Qiu
    Chen, Cheng
    Lu, Hai-Jie
    Xu, Ben-Hua
    JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1749 - 1755
  • [43] First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
    Li, Jin
    Chen, Zhendong
    Bai, Yuxian
    Liu, Bo
    Li, Qingshan
    Zhang, Jingdong
    Zhou, Jun
    Deng, Ting
    Zhou, Fuyou
    Gao, Shegan
    Yang, Shujun
    Ye, Feng
    Chen, Long
    Bai, Wei
    Yin, Xianli
    Cang, Shundong
    Liu, Lianke
    Pan, Yueyin
    Luo, Hui
    Ji, Yanxia
    Zhang, Zhen
    Wang, Jufeng
    Yang, Quanliang
    Li, Na
    Huang, Rong
    Qu, Chenglin
    Ni, Jing
    Wang, Bo
    Xu, Yan
    Hu, Jin
    Shi, Qingmei
    Yang, Jason
    NATURE MEDICINE, 2024, 30 (03) : 740 - 748
  • [44] The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer
    El Rassy, Elie
    Abboud, Rita Maria Khoury
    Ibrahim, Nathalie
    Assi, Tarek
    Aoun, Fouad
    Kaftan, Joseph
    IMMUNOTHERAPY, 2018, 10 (12) : 1047 - 1052
  • [45] Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
    Liu, Shixian
    Dou, Lei
    Wang, Kaixuan
    Shi, Zhao
    Wang, Ruixue
    Zhu, Xiaohong
    Song, Zehua
    Li, Shunping
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 683 - 690
  • [47] Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review
    Zhu, Kanghao
    Chen, Hui
    Xu, Congcong
    Chen, Dong
    Jin, Zixian
    Ren, Sijia
    Witharana, Pasan
    Chen, Baofu
    Shen, Jianfei
    JOURNAL OF THORACIC DISEASE, 2023, 15 (03) : 1186 - +
  • [48] Current status of immune checkpoint inhibitor therapy for advanced esophageal squamous cell carcinoma
    Enomoto, Naoki
    Yamada, Kazuhiko
    Terayama, Masayoshi
    Kato, Daiki
    Yagi, Shusuke
    Wake, Hitomi
    Takemura, Nobuyuki
    Kiyomatsu, Tomomichi
    Kokudo, Norihiro
    GLOBAL HEALTH & MEDICINE, 2021, 3 (06): : 378 - 385
  • [49] Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis
    Yang, Xiuli
    Zheng, Xiaochun
    Hu, Sang
    Huang, Jinlong
    Zhang, Miaomiao
    Huang, Ping
    Wang, Jiangfeng
    BMC CANCER, 2024, 24 (01)
  • [50] The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
    Qian, Xiaoying
    Wang, Yong
    Liu, Fanrong
    Yuan, Yong
    Fang, Chen
    Zhang, Xinwei
    Yuan, Shangkun
    Chen, Renfang
    Yu, Biao
    Wang, Tong
    Yin, Yan
    Li, Yong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345